I didn't want to give specific timeframes. This is what I said:
A good outcome from the COVID ARDS trial could move us to $8.85 ballpark relatively quickly. As for the $17 valuation ... the market is forward-looking and it really comes down to timelines for commercialisation of Pediatric and Adult GVHD treatment ( these make up about 30% of the overall $17 valuation ). My perspective is that once revenues are coming in for Pediatric GVHD, the market will start to price in revenues for Adult GVHD.
- Risk-adjusted value @ $8.85 for Adult GVHD, Pediatric GVHD and COVID ARDS
(potential future target for this group @ $17)
Note - Advanced Heart Failure and Chronic Low Back Pain are not included in the $17 target and we have reports from trials expected around mid year.
Tracking Valuations, page-23
-
- There are more pages in this discussion • 300 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |